{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=93", "query": { "intervention": "Blinded (placebo)", "page": 93 }, "page_size": 10 }, "pagination": { "page": 93, "page_size": 10, "total_count": 2216, "total_pages": 222, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=94&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=92&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T17:08:08.692Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01244880", "title": "Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Saline", "type": "OTHER" }, { "name": "PF-02545920", "type": "DRUG" }, { "name": "Ketamine", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "21 Years to 45 Years" }, "enrollment_count": 4, "start_date": "2011-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2014-03-21", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 3, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01244880" }, { "nct_id": "NCT02943096", "title": "Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Major Depressive Disorder" ], "interventions": [ { "name": "CocoaVia", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 6, "start_date": "2016-11", "completion_date": "2018-02-06", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943096" }, { "nct_id": "NCT07783542", "title": "ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "ORKA-002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Oruka Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 200, "start_date": "2026-08-21", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" }, { "city": "Sandy Springs", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783542" }, { "nct_id": "NCT03568318", "title": "A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Topical corticosteroids (TCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 1533, "start_date": "2018-08-09", "completion_date": "2030-10-23", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03568318" }, { "nct_id": "NCT05169190", "title": "Stellate Ganglion Block for PTSD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Post-traumatic Stress Disorder" ], "interventions": [ { "name": "Stellate Ganglion Block", "type": "PROCEDURE" }, { "name": "Sham Stellate Ganglion Block", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 410, "start_date": "2022-11-17", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 6, "location_summary": "Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169190" }, { "nct_id": "NCT05067127", "title": "Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3G", "IC-MPGN", "C3 Glomerulopathy", "C3 Glomerulonephritis", "Complement 3 Glomerulopathy", "Complement 3 Glomerulopathy (C3G)", "Complement 3 Glomerulonephritis", "Dense Deposit Disease", "DDD", "Membranoproliferative Glomerulonephritis", "Membranoproliferative Glomerulonephritis (MPGN)", "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 124, "start_date": "2021-11-12", "completion_date": "2025-01-14", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067127" }, { "nct_id": "NCT04246164", "title": "A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mild Cognitive Impairment", "Memory Disorders", "Memory Loss" ], "interventions": [ { "name": "HD-tDCS combined with CT", "type": "DEVICE" }, { "name": "sham HD-tDCS combined with CT", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 8, "start_date": "2021-01-25", "completion_date": "2023-02-23", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246164" }, { "nct_id": "NCT04947514", "title": "Use of Tranexamic Acid in Reduction Mammoplasty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hematoma Postoperative", "Venous Thromboembolism" ], "interventions": [ { "name": "Tranexamic acid", "type": "DRUG" }, { "name": "Placebo (topical saline)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 98, "start_date": "2021-10-29", "completion_date": "2022-07-13", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04947514" }, { "nct_id": "NCT04944784", "title": "A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Reldesemtiv", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytokinetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 489, "start_date": "2021-08-16", "completion_date": "2023-07-18", "has_results": true, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04944784" }, { "nct_id": "NCT02943447", "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Cilofexor", "type": "DRUG" }, { "name": "Placebo to match cilofexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 71, "start_date": "2016-12-01", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-11-05T17:08:08.692Z", "location_count": 13, "location_summary": "Sacramento, California • Aurora, Colorado • Lakewood Rch, Florida + 9 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood Rch", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943447" } ] }